Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP

To evaluate the efficacy and safety of chidamide monotherapy as maintenance treatment in patients with diffuse large B-cell lymphoma (DLBCL) and HBV infection following initial response to R-CHOP therapy, and to provide evidence for the clinical application of chidamide.

Trial Details

NCT ID
NCT07493109
Phase
PHASE3
Sponsor
Ou Bai, MD/PHD
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Chidamide
  • Entecavir Tablets
Locations (sample)
  • Changchun, Jilin, China|43.88,125.32278

Key Eligibility Criteria

  • Both sexes, age range ≥18 years and ≤80 years.
  • No prior treatment for DLBCL, including chemotherapy, targeted therapy, immunotherapy, local radiotherapy for lymphoma (except local radiotherapy u…
  • Histopathologically confirmed diagnosis (all of the following conditions must be met simultaneously): Diffuse large B-cell lymphoma (DLBCL), and CD…
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →